Skip to content
Open access

Substantial Change Between Repeated Lipoprotein(a) Measurements Is Associated with Residual Cardiovascular Risk in a Real-World Multicenter Cohort

Aug 2026 · Journal of Clinical Medicine · Vol 15, pp. 6527 · 0 citations · 32 references
Medicine

TL;DR

Intra-individual change in Lp(a) between two measurements is independently associated with cardiovascular outcomes but provides only modest incremental discrimination, which requires prospective validation before they can inform repeat-testing strategies.

Abstract

Background/Objectives: Lipoprotein(a) [Lp(a)] is a genetically determined, largely stable risk factor for atherosclerotic cardiovascular disease, and guidelines recommend at least one measurement during adulthood. Whether intra-individual change in Lp(a) between repeated measurements carries prognostic information beyond static risk categories in routine practice is uncertain. Methods: In a multicenter retrospective cohort from three South Korean tertiary hospitals, we studied adults with two Lp(a) measurements at least 90 days apart (2019–2024; n = 13,914). High variability was defined as an absolute change > 10 mg/dL combined with a relative change > 25%. The primary outcome was major adverse cardiovascular events (MACE), analyzed with Cox proportional hazards models adjusted for clinical covariates including baseline and follow-up Lp(a) risk categories. Results: Despite a strong rank correlation between measurements (Spearman’s ρ = 0.92), 2156 patients (15.5%) showed high variability. MACE occurred more frequently in the high-variability group (6.8% vs. 4.2%, p < 0.001), and high variability remained independently associated with MACE (adjusted hazard ratio 1.46, 95% CI 1.18–1.80). The association was consistent across multiple sensitivity analyses, persisted after excluding heart-failure hospitalization from MACE (HR 1.41), and was present for both increases and decreases in Lp(a). Incremental discrimination over a base model was modest, though statistically significant (ΔC-statistic 0.006, 95% CI 0.001–0.012; continuous net reclassification index 0.090, p < 0.001). Conclusions: Intra-individual change in Lp(a) between two measurements is independently associated with cardiovascular outcomes but provides only modest incremental discrimination. These hypothesis-generating findings require prospective validation before they can inform repeat-testing strategies.

Read PDF

Similar papers

Open access Sep 2026

Lipid Variability Predicts Long-Term Major Adverse Cardiovascular Events in MINOCA: A Retrospective Cohort Study

Objective This study investigates the predictive value of long-term variability in low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and lipoprotein(a) [Lp(a)] for major adverse cardiovascular events (MACEs) in patients with myocardial infarction with non-obstructive coronary ar...

Yan-Lin Wang, Min-Rui Diao · 0 citations
Open access Sep 2026

Lp(a), platelet count, aspirin and cardiovascular outcome: a prospective cohort analysis

Concomitant elevation of Lp(a) and platelet count identifies a subgroup of individuals at substantially higher risk for MACE, and the observed potential benefit of aspirin in the double-high subgroup is exploratory and warrants further prospective investigation.

Xuan-Ceng-Fan-Jiang Song, Jia-Xin Huang, Q. Hou et al. · 0 citations
Open access Sep 2026

Underutilization of Lipoprotein(a) Testing and Its Association with Coronary Interventions: PITT-LIPID Real-world Registry Insights

Background: Lipoprotein(a) [Lp(a)], is leading risk factor for premature atherosclerotic cardiovascular disease. Multi-societal guidelines recommend to test Lp(a) amongst adults at least once, however, real-world testing data in primary prevention populations remains scarce. Objectives: To investigate the utilization o...

R. Awan, H. Wang, F. Thoma et al. · 0 citations
Open access Aug 2026

Real-world association between elevated lipoprotein (a) and cerebrovascular and cardiovascular outcomes: A federated EHR cohort study

Elevated lipoprotein(a) (Lp(a)) is a causal cardiovascular risk factor, yet its association with incident ischemic stroke in routine clinical care remains uncertain. Adults in the TriNetX US Collaborative Network with Lp(a) ≥50 mg/dL were compared with those having Lp(a) <50 mg/dL after 1:1 propensity score matching. A...

M. Kachhadia · 0 citations
Open access Oct 2026

Inflammation and lipoprotein(a) as predictors of cardiovascular events across baseline risk levels - results from the UK Biobank.

AIMS To determine how high-sensitivity C-reactive protein (hsCRP) and lipoprotein(a) [Lp(a)] predict major adverse cardiovascular events (MACE) across the spectrum of baseline cardiovascular risk. METHODS UK Biobank participants were grouped according to baseline cardiovascular risk. The primary endpoint was first MA...

B. Tucker, Leung-Ong Kwok, Thomas Payne et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.